Eisai stock reports GBP 150 million subsidiary dividend

Published on 10/08/2026 at 08:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eisai stock was last at JPY 4,590.00 on October 8, 2026, down 1.08 percent. A GBP 150 million subsidiary dividend was resolved on October 2, 2026.

Eisai, JP3160400002, Illustration mit AI erstellt.

Eisai (ISIN JP3160400002) was last at JPY 4,590.00 on the Tokyo Stock Exchange on October 8, 2026 at 11:30 a.m. JST, down 1.08 percent from the previous close of JPY 4,640.00. The company disclosed a GBP 150 million dividend from consolidated subsidiary Eisai Europe Ltd. on October 2, 2026, according to Japan IR.

GBP 150 million enters the picture

The dividend resolution took place on October 2, 2026, and receipt was expected in early October, the linked company disclosure states. Eisai Europe Ltd. is a consolidated subsidiary, while the receipt is scheduled to be recognized as non-operating income in Eisai's standalone financial statements.

The disclosure also draws a clear accounting boundary: the dividend has no impact on consolidated results. For investors, that makes the payment a balance-sheet and parent-company item rather than a change to the group's operating earnings.

First-quarter growth reaches 16 percent

Eisai's first-quarter fiscal 2027 revenue reached JPY 234.3 billion, up 16 percent from JPY 202.7 billion in the comparable period, according to Simply Wall St. Net income was JPY 18.2 billion, compared with JPY 14.5 billion a year earlier, while profit margin increased to 7.8 percent from 7.1 percent.

First-quarter EPS came in at JPY 64.71, up from JPY 51.35 in the year-earlier period. Simply Wall St reported that revenue exceeded analyst estimates by 8.0 percent and EPS exceeded estimates by 16 percent, giving the latest operating update more weight than the subsidiary dividend alone.

Stock stays below the yearly high

At JPY 4,590.00 on October 8, 2026, Eisai stock stood JPY 653.00 below its 52-week high of JPY 5,243.00 and JPY 930.00 above its 52-week low of JPY 3,660.00. The market capitalization was JPY 1.3 trillion, and trading volume reached 351,800 shares.

The next scheduled reporting date is November 10, 2026. The near-term investor test is whether the 16 percent first-quarter revenue increase can translate into sustained earnings growth while the Leqembi and oncology portfolios carry the group's expansion plans.